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Atherogenic dietThe aim of the present study is to investigate the protective effect of L-cysteine (Cys) on protein glycation, and
hence, the improvement of diabetic complications. Streptozotocin-induced diabetic rats on an atherogenic diet
were used as a model. Two groups of rats, normal and diabetic, were treated with 0.05% of Cys in drinking
water for 3 months and two others received water only. Some parameters including: glucose, insulin, glycation
products, activity of the glyoxalase system, lipid proﬁle, oxidationmarkers, high sensitivity CRP (Hs CRP) and cre-
atinine in the serum, and protein in the urine of all rats were determined. Furthermore, rat serum albumin and
LDL were puriﬁed and incubated with glucose in the presence and absence of Cys and the samples were investi-
gated for glycation and oxidation products. Cys showed an inhibitory effect on glycation and oxidation products
in both in vivo and in vitro conditions. It reduced glucose, insulin resistance, triglyceride, cholesterol, LDL, Hs CRP
and creatinine in the serum; and the proteinuria; furthermore, it increased HDL and glyoxalase system activity in
the serum of the diabetic–atherosclerotic rats. Cys reduced all of the risk factors of diabetic complications and
showed anti-atherosclerotic potential; thus it is useful in diabetes treatment.
© 2014 Elsevier Ltd. All rights reserved.Introduction
Hyperglycemia induces ROS1 overproduction (Du, Miller, & Kern,
2003). Excess formation of ROS in addition to the disorder in the status
of the antioxidant defense system, plays a critical role in diabetes-related
vascular complications. GSH2 is involved in the antioxidant defense sys-
tem and its deﬁciency contributes to pathogenesis of diabetes (Wu,
Fang, Yang, Lupton, & Turner, 2004). Cys3 availability has been consid-
ered as a major rate limiting factor in glutathione production (Grifﬁth,
1999). It has been shown that the levels of both Cys and GSH decreased
in diabetes (Sekhar et al., 2011).
In addition, hyperglycemia induces glycation of biomacromolecules
and the formation of AGEs.4 All of the early, intermediates and ﬁnaldicine, University of California,
ucla.edu (S.Z. Bathaie).AGEs are involved in the initiation and development of vascular diabe-
tes complications (Brownlee, 1995; Cohen, 2003). Elevated levels of
the g-Alb5 are associated with the metabolic disorders observed in dia-
betes mellitus (Brownlee, 1995; Cohen, 2003). It has been reported that
inhibiting excess non-enzymatic glycation of serum albumin improves
renal abnormalities and protects against the development of renal in-
sufﬁciency (Cohen et al., 2000).
Carbonyl stress is a phenomenon responsible for activation of a se-
ries of inﬂammatory responses leading to accelerated vascular damage
in diabetes (Baynes & Thorpe, 1999). Endogenous products of α-
oxoaldehydes, such as GO6 and MG7 , are the key factors involved in
this phenomena.
Elevated levels of circulating AGEs are associatedwith diabetics, par-
ticularly those with renal insufﬁciency, because these products are nor-
mally excreted in the urine (Muri, 1954). AGEs are nephrotoxic both
in vitro and in vivo (Vlassara et al., 1994; Yamagishi et al., 2003). It
has been shown that pharmacological intervention in AGE formation
protects against structural lesions, proteinuria and renal function loss
in experimental diabetes (Alderson et al., 2004).5 Glycated albumin.
6 Glyoxal.
7 Methylglyoxal.
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plasma lipoproteins in patientswith diabetes. In poorly controlled type1
diabetes, in addition to ketoacidosis and hypertriglyceridemia, in-
creased Chol8 and LDL9 and reduced HDL10 commonly occur. An in-
crease in dietary Chol favors the development of glomerulosclerosis
(French, Yamanaka, & Ostwald, 1967; Wellmann & Volk, 1971). Lower-
ing the serum Chol of the diabetic rat has improved the renal function
and signiﬁcantly decreased the formation of AGEs (Metz, Alderson,
Thorpe, & Baynes, 2003).
PU11 is an important marker for DN12 (Abbate, Zoja, & Remuzzi,
2006) that potentially used as a surrogate marker for advanced athero-
sclerosis (Marso et al., 1999), CKD13 and CVD.14 It can also be used for
monitoring the therapeutic efﬁcacy (Mitch, Shahinfar, Dickson, de
zeeuw, & Zhang, 2004).
The beneﬁcial effect of L-lysine (Jafarnejad, Bathaie, Nakhjavani,
Hassan, & Banasadegh, 2008) and L-glycine (Bahmani, Bathaie,
Aldavood, & Ghahghaei, 2012), as the chemical chaperones of amino
acid family, on diabetes complication has been recently studied in our
Lab. Here, we investigated the effect of Cys in the early to end products
of albumin glycation, as a model protein. The effects of three month Cys
therapy on the glycation and oxidation of LDLwere also studied in vitro.
All of these parameters were also determined in vivo. In addition, lipid
proﬁle, insulin resistance, markers of oxidation, inﬂammation, and kid-
ney function, aswell as the atheromatous plaque formationwere inves-
tigated in diabetic rat on atherogenic diet.Materials and methods
Materials
Dihydroxyacetone, sodium carbonate, sodiummono and dihydrogen
phosphate, Iodoacetamide,15 Glc,16 sodium azide, acetonitrile, ethanol,
trichloroacetic acid,17 2,4-dinitrophenylhydrazine, potassium iodide,
cyclohexane, heptaﬂuorobutyric acid, CuSo4, thiobarbituric acid,
Chol, cholic acid, Cys (L-cysteine hydrochloride monohydrate),
2-methylpropanol, CaCl2, NaCl and EDTA from Merck Chemical Co.
STZ,18 GO, MG, NBT,19 oxalic acid, 5-hydroxymethylfurfuraldehyde,20
and Triton X-100, were purchased from Sigma Chemical Co. The
0.45 μm syringe ﬁlters were obtained from Millipore. Standard of PEN21
was gifted by Professor Dr. V. M. Monnier.Animal study
Induction of diabetes and atherosclerosis, and treatment of rats with Cys
Male Wistar rats, 8 weeks old and weighing 180 ± 15 g, were pur-
chased from the Pasteur Institute of Iran, Karaj. Animals were housed
under controlled temperature with a 12 hour light and dark cycle with
free access to food and water. Two weeks later they were randomly di-
vided into four groups, and after overnight fasting, two groups received
a single injection (i.p.22) of STZ (45 mg/kg body weight in Na-citrate
buffer, pH 4.5) (Méndez & Ramos, 1994). After three days rats with8 Cholesterol.
9 Low density lipoprotein.
10 High density lipoprotein.
11 Proteinuria.
12 Diabetic nephropathy.
13 Chronic kidney disease.
14 Cardiovascular disease.
15 IAM.
16 D-glucose.
17 TCA.
18 Streptozotocin.
19 Nitroblue tetrazolium chloride.
20 5-HMF.
21 Pentosidine.
22 Intraperitoneally.FBS23 N11 mM were accepted as diabetic. Two other control groups
were injected with a vehicle only.
Thus, the experiment was carried out on four groups of rats (#10 rats
in each group) that were named as follows: normal rats (N), normal rats
treatedwith Cys (NT), diabetic rats (D), and diabetic rats treatedwith Cys
(DT). They were fed either a standard chow diet, N and NT groups, or an
atherogenic diet (Chow diet containing 1% cholesterol and 0.5% cholic
acid), D and DT groups. The treatment of NT and DT groups with Cys
(0.05% in drinking water) began on the ﬁrst week of diabetes induction.
Itwas chosen according to the literature (Sagara et al., 1994) and our per-
sonal experience. Based on the solubility of Cys in water (50 mg/ml,
Sigma-Aldrich Product Information) and preventing the stress induced
by gavage (Brown, Dinger, & Levine, 2000), this amino acid was added
in drinking water; similar to our previous studies (Bahmani et al., 2012;
Jafarnejad et al., 2008). The study continued up to the end of three
months. A 24-hour urine specimen was collected at the end of the third
month, by transferring and keeping rats in individual metabolic cage
for 24 h. Then, after 16 h of fasting, rats were anesthetizedwith an i.p. in-
jection of ketamine–xylosine (90 + 10 mg/kg body mass) and their
blood was collected from the heart and transferred into test tubes with
and without EDTA. Serum samples were prepared by 15 min centrifuga-
tion of blood at 5000 ×g and were stored at−70 °C until testing.
The experimental protocolwas approved by the animal Ethical Com-
mittee in accordance with the guidelines for the care and use of labora-
tory animals prepared by Tarbiat Modares University.
Determination of biochemical parameters
FBS, TG,24 Chol and HDL were measured by enzymatic colorimetric
methods; LDL was calculated from the Friedwald equation (Jafarnejad
et al., 2008). Cr25 was measured in the serum of rats using the Jaffe ki-
netic method (Pars Azmune, Tehran, Iran).
The serum insulin level was determined by ELISA26 using a rat insu-
lin kit (Mercodia, Uppsala, Sweden). Then the HOMA-IR27 and pancreas
cell function were calculated using Eq. (1):
HOMA‐IR ¼ fasting insulin U=mlð Þ  fasting glucose mM½ ð Þ=22:5½ : ð1Þ
Determination of AOPP28 in the serum
AOPPwas determined according to themethod ofWitko-Sarsat et al.
(1996). Brieﬂy, 200 μl of serum diluted 1:5 with PBS,29 200 μl of chlora-
mine T (0–100 μM) for calibration and 200 μl of PBS as blank were ap-
plied. Then, 10 μl of potassium iodide (1160 mM) and 20 μl of glacial
acetic acid were added and the absorbance of the solution was immedi-
atelymeasured at 340 nm, using a Shimadzu SpectrophotometerModel
UV-3100 (Tokyo, Japan). Concentration of AOPPwas expressed in chlo-
ramine units (μM).
Determination of glyoxalase system
The activity of glyoxalase system including GLO-I30 and GLO-II31 was
measured in hemolysate. The activity of GLO-Ι was assayed at 37 °C by
measuring the initial rate of formation of S-D-lactoylglutathione. The
assay mixture contained a ﬁnal volume of 1 ml, 100 mM sodium phos-
phate buffer, pH 7.2; 3.5 mM of MG; 1.7 of mM GSH and 16 mM of
MgSO4. The mixture was incubated for 10 min followed by the addition
of 20 μl of hemolysate and the absorption at 240 nmwas read after 2min.
The activity of GLO-ΙΙwas assayed bymeasuring the initial rate of hy-
drolysis of S-D-lactoglutathione to GSH and D-lactic acid. The initial23 Fasting blood sugar.
24 Triglyceride.
25 Creatinine.
26 Enzyme-linked immunosorbent assay.
27 Homeostasis model assessment of insulin resistance.
28 Advanced oxidation protein products.
29 Phosphate buffered saline.
30 Glyoxalase Ι.
31 Glyoxalase ΙΙ.
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pH 7.4; and the rate of its hydrolysis (after adding hemolysate) was
followed bymeasuring the absorbance at 240 nmafter 2min. The activ-
ities of GLO-Ι and GLO-ΙΙ were expressed as unit/ml (U/ml) (Sharma &
Kale, 1993).Determination of glycated products in the serum of rats
The FA32 (glycated proteins in the serum) and g-Albwere quantiﬁed
by a colorimetric method usingNBT (Xu et al., 2002). Brieﬂy, 50 μl of the
sample was incubated with 100 μl of IAM (5 mM) for 30 min at 37 °C.
Then, 1000 μl of NBT reagent (200 mM carbonate buffer, pH 10.3, con-
taining 500 μM NBT and 2% Triton X-100) was added and incubated
for 30 min at 37 °C. The absorbance of the sample was measured at
530 nm on a spectrophotometer. The dihydroxyacetone, between 0
and 1000 μM, was used as a standard to draw the calibration curve.
For measuring g-LDL,33 LDL was isolated by using the heparin pre-
cipitation method (Gavella, Lipovac, Car, & Vucic, 2002) from the rat
serum. LDL precipitate was collected by centrifugation, washed twice
with 0.2 M CaCl2 and dissolved in 5% NaCl containing 0.5% EDTA
(Cornwell & Kruger, 1961). After that, 0.9 M oxalic acid (v:v 1:2) was
added and the samples were incubated at 85 °C for 20 h. After cooling,
proteins were precipitated by adding TCA (up to 10%) and the superna-
tants were assayed for glycated products. In this method, after addition
of oxalic acid and boiling, glucose is dehydrated and 5-HMF is produced
as a chromogen by adding thiobarbituric acid. The standard curve was
plotted using 5-HMF (Fluckiger & Gallop, 1984).
GO andMGweremeasured by HPLC (Deng & Peter, 1999). TheHPLC
system consisted of a KNAUER, Smartline Manager 5000 manual,
Smartline pump1000, a SmartlineUV detector 2000 (KNAUER Corpora-
tion, Germany) and an analytical column, KNAUER C18 (250 mm
4.6 mm; 5 μ). The DNPH derivatives of GO and MG calibrators were
used for chromatography assay. The elution was isocratic with 20 mM
phosphate buffer, pH 4.6, containing 32% acetonitrile and 8% of 2-
methylpropanol at a ﬂow rate of 1.0 ml/min. The DNPH derivatives
were analyzed via a UV-detector at 330 nm.
PEN was measured by the modiﬁed method of Słowik-Żłka et al.
(2004) in order to undertake the experiment in a shorter run time.
The HPLC system consisted of a KNAUER HPLC system with an Rf-
10AXL Shimadzu ﬂuorescent detector and the same column as above.
The chromatography assay was brieﬂy undertaken as follows: 100 μl
of the sample was lyophilized and then hydrolyzed by 50 μl of 6 N HCl
at 110 °C under nitrogen atmosphere for 16 h, and subsequently neu-
tralized with 100 μl of NaOH (5 M) and 200 μl of 500 mM of phosphate
buffer (pH 7.4), and then ﬁltered through a 0.45 μm Millipore ﬁlter.
After that, it was diluted 20-fold with PBS. Filtered samples (50 μl)
were then injected into a C-18 reverse-phase analytical column using
an online ﬂuorescence detector at excitation/emission wavelengths of
335/372 nm. A linear gradient of three eluents (A, B and C) was used.
Eluent A was 10 mM of HFBA34 in water and eluent B was 25% acetoni-
trile + 75% H2O + 10 mM of HFBA; and eluent C was acetonitrile. The
elution proﬁle was as follows: 0 to 7 min, 60% A and 40% B; 7 to
11 min, 100% C; 11.5 to 15 min, 60% A and 40% B. The ﬂow rate was
maintained at 1.2 ml/min through the chromatographic run.
The AGEs were determined according to the method of Kalousova,
Skrha, & Zima (2002). The sample was diluted 1:50 with phosphate
buffer (pH 7.4) and ﬂuorescence intensity was recorded at the emission
maximum (440 nm) upon excitation at 370 nm using the spectroﬂuo-
rometer Shimadzu, Model RF-5000 (Shimadzu, Kyoto, Japan). Fluores-
cence intensity35 was expressed as arbitrary units.3632 Fructosamine.
33 Glycated LDL.
34 Heptaﬂuorobutyric acid.
35 FI.
36 AU.Determination of the effectiveness of treatments on glycation inhibition
The percentage of inhibition of the glycated product was calculated
according to Eq. (2) (Beisswenger, Moore, Brinck-Johnsen, & Curphey,
1993), by using the data of Table 1 for g-Alb, GO, MG, PEN, AGEs in
the presence or absence of Cys.
Glycationinhibition %ð Þ ¼ 100 1− DT−Nð Þ
D−Nð Þ
 
ð2Þ
where N, D andDTwere the values of the desired product in the normal,
diabetic–atherosclerotic and diabetic–atherosclerotic rats under treat-
ment, respectively.
Determination of LDL glycation and oxidation products
For estimation of LDL oxidation by the baseline level of diene conju-
gation37 in LDL lipids, the following procedure was used. At ﬁrst the
lipids were extracted from LDL samples (100 ml) by chloroform–
methanol (2:1), dried under nitrogen, then redissolved in cyclohexane,
and analyzed spectrophotometrically at 234 nm. Absorbance units
were converted to molar units using the molar extinction coefﬁcient
of 2.95 × 104 M−1 (Ahotupa et al., 1998). For measuring the OFP38 of
LDL, dried residues were diluted 20 times with phosphate buffer
100 mM, pH 7.4; and the emission was measured at 430 nmwith exci-
tation at 360 nm (Esterbauer, Gebicki, Puhl, & Jürgens, 1992).
Determination of HS CRP
Hs CRP39 was measured with CUSABIO ELISA kit (Wuhan, Hubei,
China).
Determination of protein in the urine
Protein in the urine was measured with turbidimetric method
(Shahangian, Brown, & Ash, 1984). Brieﬂy, 100 μl of TCA 3% was added
to 1 ml of distilled water, sample and protein calibrator, respectively.
Absorption of sample after 5min was compared with protein standards
at 420 nm.
Pathological study
At the end of the experiment, the animals were killed and their
whole aortas were collected and any adhering tissue was removed. All
specimens were ﬁxed in 10% buffered formalin, processed and parafﬁn
embedded. Transverse and longitudinal sections of each segment were
submitted on one cassette. Then using H&E the sections were stained
and sent for pathological examination to a pathologist.
The in vitro experiments
Puriﬁcation of RSA and its incubation in different situation
Rat serum albumin40 was extracted using TCA and ethanol, by the
modiﬁed method of Ohkawara et al. (2002).
Then, three series of the duplicated tubes containing, Alb (10 mg/ml
of RSA), Alb + Glc, (10 mg/ml RSA+ 50 mMGlc) and Alb + Glc + Cys
(same concentrations of RSA and Glc + 0.05% Cys) were incubated for
3 months at 37 °C. Each solution was prepared in 100 mM sodium
phosphate buffer containing sodium azide (0.1 mM), to prevent degra-
dation (Vinson&Howard, 1996) and inhibit bacterial growth (Dearlove,
Greenspan, Hartle, Swanson, & Hargrove, 2008), and EDTA (1 mM) to
prevent artiﬁcial oxidation (Brown, Mahroof, Cook, Van Reyk, &
Davies, 2006). The reaction mixtures were then sterilized by ﬁltration
(0.45 μm pore ﬁlter). The aliquots of samples were prepared after
21 days formeasuring g-Alb, GO andMG; and after 90 days for determi-
nation of AGEs and PEN. All aliquots were maintained at−70 °C until37 DC.
38 Oxidation ﬂuorescent product.
39 High sensitivity C-reactive protein.
40 RSA.
Table 1
The effect of Cys on FBS, insulin, HOMA-IR, glycation products (FA, g-Alb, g-LDL, GO,MG, PEN and AGEs), and Cr in the serum and protein in the urine (PU) of the normal and diabetic rats
with or without receiving Cys.
Row Parameter Unit Groups
N NT D DT
1 FBS mM 4.48 ± 0.25b 5.04 ± 0.20b 15.55 ± 0.46a 9.45 ± 0.33a,b
2 FA μM 150.00 ± 8.80b 126.00 ± 7.60a,b 626.00 ± 41.20a 477.00 ± 28.30a,b
3 g-Alb 80.00 ± 4.60b 67.70 ± 4.40a,b 402.00 ± 20.70a 316.00 ± 14.40a,b
4 g-LDL 51.13 ± 1.70b 38.06 ± 0.85a,b 185.90 ± 6.77a 144.50 ± 7.48a,b
5 GO 15.60 ± 0.80b 13.70 ± 0.70b 103.80 ± 6.00a 46.20 ± 3.00a,b
6 MG 16.80 ± 0.95b 11.90 ± 0.80b 93.00 ± 5.10a 43.30 ± 3.30a,b
7 PEN 42.00 ± 2.73b 37.70 ± 6.10b 446.00 ± 20.70a 348 ± 17.00a,b
8 AGEs FI, A.U 47.66 ± 2.90b 39.70 ± 4.80b 363.70 ± 19.00a 148.3 ± 6.60a,b
9 Insulin μU/ml 17.49 ± 1.36b 17.66 ± 1.45b 8.98 ± 0.60a 11.51 ± 1.04a,b
10 HOMA-IR 3.78 ± 0.18b 3.55 ± 0.15b 6.2 ± 0.35a 4.84 ± 0.27a,b
11 Cr μM 61.50 ± 4.24b 57.70 ± 4.09b 96.50 ± 5.74a 74.25 ± 4.32a,b
12 PU mg/24 h 13.00 ± 0.90b 9.41 ± 0.80b 347.50 ± 17.50a 115.58 ± 5.94a,b
a Indicates signiﬁcance of data comparing group N with other groups (P b 0.001).
b Indicates signiﬁcance of data comparing group D with other groups (P b 0.001).
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times and if there was uncompatibility, the experiment was repeated.
The g-Alb, MG, GO, PEN and AGEs in the reaction mixtures were mea-
sured using the methods explained in Section 2.3.2.
Puriﬁcation of LDL and determination of its glycation and
oxidation products
LDL was isolated with heparine from the serum of normal rats and
incubated in the same conditions as explained in Section 2.3.1, for one
week. The samples were then separated for measurement of g-LDL
and oxidated LDL using themethods explained in Section 2.2.7. In addi-
tion, the oxidative modiﬁcation of both native and glycated LDL by
CuSO4 in the presence or absence of Cyswas compared photometrically,
by measuring the lag phase of conjugated diene formation at 234 nm
(Esterbauer, Striegl, Puhl, & Rotheneder, 1989).
Determination of the effectiveness of treatments on glycation inhibition
The percentage of inhibition of the glycated product in the in vitro
condition was calculated according to Eq. (2) and the data presented
in Table 5 for RSA (N), RSA + Glc (D) and RSA + Glc + Cys (DT).
Statistical analysis
All datawere expressed asmean±S.D. Statistical comparisonswere
performed by Tukey HSD multiple analysis of variance (MANOVA) test.
The correlation between PU and other clinical variableswas determinedFig. 1. The percentage of the inhibitory effect of Cys on the formation of the early, interme-
diates and end products of glycation in the diabetic–atherosclerotic rats treated with Cys.by multiple regression analysis using SPSS version 16 Statistical, signif-
icance was deﬁned as P b 0.05.
Results
The results of the in vivo experiment
Table 1 represents the levels of FBS, insulin, HOMA-IR, various
glycation products and Cr in the sera and PU of all groups of rats. All of
the named parameters were signiﬁcantly (P b 0.001) increased in the
diabetic group in comparison with the normal group, except insulin se-
cretion which decreased due to diabetes induction. Cys could, at least
partially, compensate for (P b 0.001) these changes in diabetic rats.
Comparing the data of normal groups with or without Cys treatment
showed that except in the FA, g-Alb and g-LDL, therewere no signiﬁcant
changes in the other parameters. This indicates the beneﬁcial effect of
Cys treatment, even in the normal rats.
As indicated in Table 1, the inhibitory effect of Cys on all of the early,
intermediates and end products of glycation (FA, g-Alb, g-LDL, MG, GO,
PEN and AGE) in the serum of diabetic rats was not the same. Thus, the
percentage of inhibition of each of themwas calculated using the data in
Table 1 and Eq. (2), and is shown in Fig. 1.
Cys therapy signiﬁcantly (P b 0.001) reduced the increased level of
serum Cr in diabetic rats. It also signiﬁcantly (P b 0.001) decreased the
protein excretion in the urine of diabetic rats.
The effect of Cys on lipid proﬁle is shown in Table 2. The normal and
diabetic groups under the treatment with Cys showed signiﬁcantly
(P b 0.001) lower levels of TG, Chol and LDL in comparison with the di-
abetic group without treatment, but their HDL level was signiﬁcantly
higher.
Comparison of the effect of the treatment on oxidation markers in-
cluding DC, FOP and AOPP, as well as the inﬂammatory marker, Hs
CRP, is shown in Table 3. The activities of GLO-I and GLO-II in all of theTable 2
The effect of L-Cys on lipid proﬁle in normal and diabetic ratswithout (N&D, respectively)
or with Cys treatment (NT & DT, respectively).
Row Group
name
TG Chol HDL LDL
mM
1 N 0.93 ± 0.02b 2.22 ± 0.07b 1.40 ± 0.05b 0.039 ± 0.01b
2 NT 0.75 ± 0.03a,b 1.79 ± 0.05a,b 1.08 ± 0.03 a,b 0.35 ± 0.01b
3 D 2.83 ± 0.12a 6.46 ± 0.24a 0.43 ± 0.01a 4.75 ± 0.24a
4 DT 1.47 ± 0.06a,b 5.63 ± 0.11a,b 0.61 ± 0.02a,b 4.35 ± 0.20a,b
a Indicates signiﬁcance of data comparing group N with other groups (P b 0.001).
b Indicates signiﬁcance of data comparing group D with other groups (P b 0.001).
Table 4
Correlation between proteinuria (PU) with Glc, insulin, HOMA-IR, glycation products
(g-Alb, GO, MG, PEN and AGEs), lipid proﬁle (TG, Chol, HDL and LDL), oxidation markers
(DC, OFP and AOPP), Cr, glyoxalase system (GLO-I and GLO-II) and Hs CRP in the
diabetic–atherosclerotic rats treated with Cys.
Parameter r P value b
Glc 0.993 0.001
Insulin −0.923
HOMA-IR 0.955
FA 0.961
g-Alb 0.947
g-LDL 0.878
GO 0.987
MG 0.989
PEN 0.943
AGEs 0.993
TG 0.987
Chol 0.925
HDL −0.902
LDL 0.900
Cr 0.948
DC 0.987
OFP 0.899
AOPP 0.969
GLO-Ι −0.940
GLO-ΙΙ −0.967
Hs CRP 0.905
Table 3
Comparison between DC, FOP, AOPP and Hs CRP in different groups of rats. N, normal; D,
diabetic–atherosclerotic; NT andDT, normal and diabetic groups received Cys, respectively.
Group DC
(μM)
FOP
(AU)
AOPP
(μM)
Hs CRP
(ng/ml)
235 ± 13.07b 28.85 ± 0.99b 248.80 ± 12.11b 15.98 ± 0.90b N
232 ± 12.99b 19.65 ± 1.06a,b 245.33 ± 13.71b 12.95 ± 0.66b NT
596.13 ± 32.66a 89.1 ± 3.25a 514.66 ± 22.37a 108.33 ± 8.40a D
554.50 ± 29.63a,b 64.27 ± 3.89a,b 487.11 ± 18.92a,b 67.61 ± 5.67a,b DT
a Indicates signiﬁcance of data comparing group N with other groups (P b 0.001).
b Indicates signiﬁcance of data comparing group D with other groups (P b 0.001).
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creased all of the oxidation products; however, the levels of DC, OFP,
AOPP and Hs CRP decreased signiﬁcantly (P b 0001) in the diabetic
group treated with Cys. Furthermore, the decreased glyoxalase activity
system (both GLO-I and GLO-II) in diabetic group (D) was signiﬁcantly
(P b 0001), but not completely, compensated for in the diabetic group
under treatment (DT).
The correlation between PU and other measurable parameters are
presented in Table 4 All parameters, except HDL, insulin andGLO system
activity, showed a high positive correlationwith PU. The level of themul-
tiple correlation coefﬁcient with PU (R= 0.892) indicates a high level of
prediction. These parameters signiﬁcantly predict PU (F = 556.87
(11, 12), P b 0.005).
The effect of Cys on atheromatous plaque formation in diabetic–ath-
erosclerotic rats in comparison with the normal group is shown in
Fig. 3a and b. As the results show, the atheromatous plaque was only
formed in the diabetic–atherosclerotic rats.
The results of the in vitro study
The inhibitory effect of Cys on the formation of various glycation
products of RSA in the presence of Glc, is presented in Table 5. SinceFig. 2. The activities of the glyoxalase Ι (a), and glyoxalase ΙΙ (b) in different groups.
(a) Indicates signiﬁcance of data comparing group N with other groups (P b 0.001).
(b) Indicates signiﬁcance of data comparing group D with other groups (P b 0.001).this inhibitory effect was not similar on all of the named products, the
percent of inhibition of each of the g-Alb, MGO, GO, PEN and AGE in
the in vitro condition was calculated using Eq. (2) and shown in Fig. 4.
Fig. 5 compares the contribution of each of the Maillard reaction
products to a total (100%) inhibition of glycation by Cys in both
in vivo and in vitro conditions.
The effect of Cys on the inhibition of the formation of glycation and
oxidation products of LDL is presented in Table 6. As the results indicat-
ed in the presence of Glc, concentrations of all of the glycated, diene
conjugation and ﬂuorescent oxidation products of LDL were increased,
but in the presence of Cys, their production was much less.
Discussion
In this study the beneﬁcial effects of three month Cys treatment on
preventing the atheromatous plaque formation and lowering the risk
of diabetic complications, including cardiovascular and renal risk fac-
tors, are shown. Cys therapy signiﬁcantly reduced hyperglycemia, and
the concentration of various glycated and oxidation products, improved
the lipid proﬁle and inﬂammatorymarker, decreased Cr and PU, and in-
creased glyoxalase system activity in the diabetic rats fed atherogenic
diet. In addition, the inhibitory effect of this treatment on the in vitro
glycation of RSA and LDL was demonstrated; a signiﬁcant correlation
was also observed between the in vivo and in vitro results.
The early, intermediates (Lu et al., 2011) and end products (Sourris
& Forbes, 2009) of theMaillard reaction have a signiﬁcant role in the de-
velopment of nephropathy and accelerated atherosclerosis in diabetes.
Thus, using strategies to prevent the formation of these products, in ad-
dition to controlling blood Glc, could reduce the risk of the diabetes
complications. As indicated in the previous studies, the results obtained
here indicate that after diabetes induction, the atherogenic diet serious-
ly increased the risk of both ND and CVD in rats.
The beneﬁcial role of sulfur containing amino acids in the control of
hyperglycemia has been considered in a recently published review
paper (Manna, Das, & Sil, 2013). Here we showed that treatment of the
diabetic–atherosclerotic ratswith Cys reduced FBS. The hypoglycemic ef-
fect of this amino acid has also been previously reported in ZDF41 rats
(Jain, Velusamy, Croad, Rains, & Bull, 2009) and in diabetic rats under41 Zucker diabetic fatty.
Fig. 3. The effect of the desired treatments on atheromatous plaque formation in normal and diabetic–atherosclerotic rats (stained byH&E; originalmagniﬁcation ×200). (a) Normal aorta
in diabetic group treated with Cys and normal group. (b) Atheromatous plaque formation in untreated diabetic group.
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Sarha, & Ismail, 2013). In contrast, some published data indicated that
Cys (200 mg/Kg) therapy by gavage, alone or in combination with tau-
rine, had no effect on blood glucose level of diabetic rats, even after
8 weeks (Tappia, Xu, Rodriguez-Leyva, Aroutiounova, & Dhalla, 2013)
The hypoglycemic effect of other amino acids like Lys (Jafarnejad et al.,
2008) andGly (Bahmani et al., 2012) in the diabetic rats has also been re-
ported by us. However, the present results show that lower concentra-
tions of Cys, than the mentioned amino acids, are needed to decrease
the FBS.
The beneﬁcial effect of Cys on insulin sensitivity of diabetic rats
shown here, conﬁrms previous reports (Jain et al., 2009; Salman et al.,
2013). Based on the results of the calculated HOMA-IR, it can be con-
cluded that the mechanism of hypoglycemic activity of Cys is possibly
through improving the pancreatic β-cells, which is consistent with the
antioxidant property of Cys, and decreasing of insulin resistance. The
observed decrease in Hs CRP level, after Cys administration, that was in-
creased due to diabetes induction is the other reason for beneﬁcial effect
of this treatment onβ-cell function anddecreasing the inﬂammatory re-
sponse as a consequence of oxidative processes.
It has been previously reported that Cys treatment inhibited the
glycation of hemoglobin in ZDF (Jain et al., 2009). Hemoglobin is a cyto-
solic protein extensively found in RBC. In the present study, we investi-
gated the effect of Cys in an extracellular protein, albumin, which is
involved in many biological processes, including osmotic pressure,
transfer of different molecules (free fatty acids, drugs, toxins, etc.) in
the blood stream and binding to various cations. In addition, we inves-
tigated the inhibitory effect of Cys on another biomacromolecule
(LDL) involved in the CVD. Our results indicated that this sulfur contain-
ing amino acid inhibited the formation of various glycated products
(MG, GO, PEN and AGEs) of RSA and LDL, with various degrees, in
both test tubes (in vitro), and in rat (in vivo). These results also indicat-
ed that the levels of FA, g-Alb and g-LDL in the normal rats received Cys
were even lower than the untreated group. Therefore, Cys therapy could
be useful to signiﬁcantly decrease the important risk factors of diabetes
complications.Table 5
The effect of Cys on the in vitro formation of various glycated products of rat serum albumin (
Row Treatment g-Alb GO
μM
1 RSA 120.00 ± 3.40 9.45 ±
2 RSA + Glc 1150.00 ± 10.10 30.45 ±
3 RSA + Glc + Cys 381.00 ± 4.20 24.10 ±The inhibitory activity of S-allyl cysteine on Amadori product
of bovine serum albumin and in vitro AGEs formation (Ahmad,
Pischetsrieder, & Ahmed, 2007), the potential of Cys and cysteamine
to trap MG (Vidal et al., 2014), and the in vitro inhibitory effect of Cys
on the early LDL oxidation (DC) have been reported (Patterson, Lamb,
& Leake, 2003). All of these reports are consistent with the observed re-
sults here.
However, as indicated in Fig. 5, the inhibitory effect of Cys on RSA
glycation products is slightly different in two situations, in vitro and
in vivo. So that, inhibition of the in vitro formation of g-Alb and PEN
wasmore than that of the in vivo. In contrast, the anti-glycating activity
of Cys against the other glycated products was stronger in the in vivo
than that in vitro. To ﬁnd the cause of these differences, we determined
the activities of the glyoxalase system, as a potent system involves in the
detoxiﬁcation of MG and other reactive aldehydes. The activities of both
GLO-I and GLO-IIwere signiﬁcantly decreased due to diabetes induction.
As the data shows, Cys treatment signiﬁcantly (P b 0.001) increased
glyoxalase system activity, in the in vivo. There are at least two possibil-
ities for these observations. First, these enzymes were glycated in the
hyperglycemic condition and because of the conformational changes,
their activities have decreased. But in the presence of a glycation inhib-
itor and an antioxidant, like Cys, their enzymatic activities were re-
stored. Similar phenomena have been previously shown in various
enzymes and proteins in the serum, plasma, extracellular matrix, cyto-
sol, and even in the nucleus by us (Bathaie, Jafarnejad, Hosseinkhani,
& Nakhjavani, 2010; Bathaie, Nobakht, Mirmiranpour, Jafarnejad, &
Moosavi-Nejad, 2011; Jafarnejad et al., 2008; Mirmiranpour, Bathaie,
Khaghani, Nakhjavani, & Kebriaeezadeh, 2012; Rahmanpour & Bathaie,
2011). Second, Cys administration raised the GSH concentration
(Grifﬁth, 1999), which in order, by increasing the substrate concentra-
tion, the activity of the glyoxalase system and thus detoxiﬁcation of
dicarbonyl compounds have increased. Both of these mechanisms
should be extensively investigated in future studies.
To continue, we investigated the effect of Cys on various parameters
involved in consequences of diabetes. The improvement effect of Cys
therapy on TG, Chol and HDL of both normal and diabetic rats wasRSA).
MG PEN AGEs
(AU)
0.10 3.85 ± 0.10 4.60 ± 0.15 55.00 ± 1.00
0.40 9.85 ± 0.20 21.80 ± 0.11 499.00 ± 5.10
0.47 6.18 ± 0.16 12.50 ± 0.23 268.00 ± 4.20
Fig. 4. The percentage of the inhibitory effect of Cys on diverse glycation products of rat
serum albumin (RSA) in the in vitro condition.
Table 6
The effect of Cys on the in vitro formation of glycated and oxidized products of LDL.
Row Treatment g-LDL DC FOP
μM AU
1 LDL 19.50 ± 0.70 16.94 ± 0.57 15.17 ± 0.44
2 LDL + Glc 328.00 ± 7.07 135.56 ± 4.55 500.01 ± 10.84
3 LDL + Glc + Cys 87.00 ± 1.41 36.60 ± 1.18 46.12 ± 1.36
915S. Mahdavifard et al. / Food Research International 62 (2014) 909–916observed, but LDL only decreased in the diabetic group treated with Cys
(P b 0.001). As indicated in the results, Cys not only reduced LDL level in
diabetic–atherosclerotic rats, but also inhibited the LDL glycation and
oxidation, thus it exerts a strong anti-atherogenic activity, which is con-
ﬁrmed by other results.
The inhibitory effect of Cys on protein oxidation (AOPP formation)
which has been previously reported in the ZDF (Jain et al., 2009), is
also shown in the present study using Wistar albino rat. This data ac-
companying with the Cys inhibitory effect on the formation of DC and
FOP (markers of early- and end-LDL oxidation), and inhibition of vari-
ous AGE products, conﬁrm the role of Cys as a strong inhibitor of ROS
formation.
Serum Cr was signiﬁcantly (P b 0.05) increased due to the diabetes
induction; however, it was signiﬁcantly reduced in this group due to
the treatmentwith Cys. The protein concentration in the urine of the di-
abetic–atherosclerotic rats was also signiﬁcantly (P b 0.005) increased;
and it was decreased due to the Cys therapy, but both of these parame-
terswere still higher than the normal levels. These results indicated that
diabetes induction accompanied with the atherogenic diet cause the in-
duction of DN in the rats, however Cys reduced the risk of this compli-
cation. A signiﬁcant decrease in microalbuminuria of diabetic rats
treated with Lys (Jafarnejad et al., 2008), and the reduction of PU in di-
abetic rat treated with L-arginine has been reported previously (Reyes,Fig. 5. Contribution of each of theMaillard reaction products to a total (100%) inhibition of
glycation by Cys in both in vitro and in vivo studies.Karl, Kissane, & Klahr, 1993), but Cys was stronger than the named
amino acids and exerts its role at lower concentration.
PU has been known as an important predictor of DN (Marso et al.,
1999) and CVD (Mitch et al., 2004). The correlation between PU with
AGEs and Chol has also been reported (Nakamura et al., 2010). Here,
the correlation between PU and each of the Glc, glycation and oxidation
products, lipid proﬁles, Hs CRP, GLO system activity and Cr was investi-
gated. As shown in Table 3, the risk of diabetic nephropathy (based on
the level of correlation) rises with the reduction of HDL, insulin and
GLO system activity and the increase of the other mentioned parame-
ters. Therefore, it is suggested that in addition to FBS, the levels of the
glycation and oxidation products could also be the predictors of the
risk of DN and CVD. As indicated in the present study, Cys as a multi-
functional compound with hypoglycemic, antioxidant and anti-
inﬂammatory activities, inhibited protein glycation, could trap the
dicarbonyl compounds (Mehta, Wong, & O'Brien, 2009) and induced
the glyoxalase system activity, which in order reduced more the level
of glycoxidation compounds. Therefore, it should be administered to
the diabetic patients to reduce the chance of diabetic complications.
In conclusion, the results of the present study indicated that Cys as a
reducing compound and a glycation inhibitor decreases all of the risk
factors of DN and CVD in diabetic–atherosclerotic rats, after the three
month treatment. In addition, diverse glycation and oxidation products,
especially GO, MG and AGEs can be determined and used as the predic-
tors of diabetic complications.
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